A Study to Assess the Effect of Surovatamig in Adult Participants With Antibody-mediated Kidney Disease
← catalyst calendarNCT07571746 · readout in 613 d
Sponsored by AstraZeneca (industry) · AZN — their whole pipeline →.
Phase
Phase 2
Status
Recruiting
Study type
Interventional
Design
Na · None · Treatment
Enrollment
43estimated
Sites
24
Countries
Belgium, France, Germany +5
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2026-03-28 | actual | When the study began enrolling |
| Primary completion | 2028-04-24 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2029-10-15 | estimated | The whole study's end, after follow-up |
| First posted | 2026-05-06 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-08-11 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Primary Membranous Nephropathy
Intervention
- Drug: Surovatamig
Primary outcomes
what the primary-completion date above is the date OFNumber of participants with adverse events.
measured Through study completion, an average of 2 years
Change from baseline in UPCR (from 24-hour urine collection or the intended 24-hour urine collection)
measured At 6 months
Permalink · AZN's whole pipeline · Catalyst calendar · Every registered study · What changed